MORRISVILLE, N.C., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today reported financial results for the second quarter ended June 30, 2024. The company will host a webcast at 8:30 a.m. ET on August 7, 2024 to discuss the financial results and provide a corporate update. Dr. Roger Jeffs, Liquidia's Chief Executive Officer, said: "We continue to face no legal impediments for t ...

- T In our previous article on Liquidia, we discussed the rich catalyst path for value unlocking, we cited significant upside potential to a target of around $16. Today, we are revisiting the opportunity in light of significant legal developments in the last few months. For starters, in recent weeks the stock price of Liquidia (NASDAQ:LQDA) took a hit as a new discussion around a potential United appeal in front of the Supreme Court emerged. We think this is an overstated risk and that there continue to be ...

Liquidia to feature two live posters sessions and five encore presentations covering its investigational products, YUTREPIA™ (treprostinil) inhalation powder and L606 (liposomal treprostinil) inhalation suspension Rajeev Saggar, MD, Chief Medical Officer at Liquidia, said: "Since 1973, the World Symposia on Pulmonary Hypertension has contributed to the ongoing scientific advancement of our field. We are delighted to present seven thematic posters on the world stage showcasing YUTREPIA and L606. We look forw ...

Liquidia to feature two live posters sessions and five encore presentations covering its investigational products, YUTREPIA™ (treprostinil) inhalation powder and L606 (liposomal treprostinil) inhalation suspension MORRISVILLE, N.C., June 18, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today the company will present seven posters related to its product pipeline at the 7th World Symposia of Pulmonary Hypertension (WSPH) taking place June 29 to July 1, 2024, in Barcelona, Spain. The ...

MORRISVILLE, N.C., June 03, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) announced today that on May 31, Judge Andrews of the U.S. District Court for the District of Delaware (District Court) denied the motion for preliminary injunction filed by United Therapeutics (UTHR) that sought to block the launch of Liquidia's YUTREPIA™ (treprostinil) inhalation powder to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). The ruling reinforces the clear path for the U.S. F ...

Liquidia Corporation (NASDAQ:LQDA) Q1 2024 Earnings Conference Call May 14, 2024 8:30 AM ET Operator IÂ'll now hand the call over to Jason Adair, Chief Business Officer. Before we begin, please note that todayÂ's conference call will contain forward-looking statements, including those statements regarding future results, unaudited and forward-looking financial information, as well as the companyÂ's future performance and or achievements. Thank you, Jason. Good morning, everyone, and thank you for joining us ...

Liquidia Technologies, Inc. (LQDA) has been beaten down lately with too much selling pressure. While the stock has lost 11.3% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier. Here is How to Spot Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum ...

Exhibit 99.1 Liquidia Corporation Reports First Quarter 2024 Financial Results and Provides Corporate Update MORRISVILLE, N.C., May 13, 2024 – Liquidia Corporation (NASDAQ: LQDA) today reported financial results for the first quarter ended March 31, 2024. The company will host a webcast at 8:30 a.m. ET on May 14, 2024 to discuss the financial results and provide a corporate update. Dr. Roger Jeffs, Liquidia's chief executive officer, said: "We continue to vigorously pursue final agency action for YUTREPIA's ...

MORRISVILLE, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) today reported financial results for the first quarter ended March 31, 2024. The company will host a webcast at 8:30 a.m. ET on May 14, 2024 to discuss the financial results and provide a corporate update. Court denied United Therapeutics' Request for Injunctive Relief in Lawsuit Against FDA. UTHR filed a separate lawsuit against FDA in the U.S. District Court for the District of Columbia (Case No. 1:24-cv00484- JDB), and ...

or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Commission File Number: 001-39724 LIQUIDIA CORPORATION ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended March 31, 2024 (Exact Name of Registrant as Specified in Its Charter) | Delaware | 85-1710962 | | - ...